Prediction of Risk of Cardiac Adverse Events After Chemotherapy Based on Acoustic Cardiography-Blood Index Nomogram
10.3971/j.issn.1000-8578.2024.23.1352
- VernacularTitle:基于心电心音图—血液指标的列线图对化疗后心脏不良事件风险的预测研究
- Author:
Yan LIU
1
;
Yuanfei LI
;
Wenping ZHANG
;
Rui JIA
;
Mei PING
Author Information
1. 030001 太原,山西医科大学公共卫生学院
- Keywords:
Acoustic cardiography;
Blood index;
Malignant tumor;
Cardiac adverse events;
Nomogram
- From:
Cancer Research on Prevention and Treatment
2024;51(6):462-468
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the risk of cardiac adverse events in patients with malignant tumors after chemotherapy by using a combination of acoustic cardiography and blood indices.Methods A total of 171 patients with malignant tumor who received chemotherapy were included.They were divided into cardiac adverse event group and non-cardiac adverse event group in accordance with whether cardiac adverse events occurred after chemotherapy.The general data,blood indices before chemotherapy,and acoustic cardiography-related indices in the early stage(1-3 cycles)of chemotherapy of the two groups were analyzed.The possible influencing factors were determined by binary logistic regression analysis,and the nomogram was drawn.The receiver operating characteristic(ROC)curve was used to evaluate the prediction ability of the nomogram.Results Cardiac adverse events occurred in 44 of 171 patients with malignant tumors after chemotherapy,and the incidence of cardiac adverse events was 25.73%.Binary logistic regression results showed that age,red blood cell distribution width(RDW)before chemotherapy,activated partial throm-boplastin time(APTT),and electromechanical activation time(EMAT)at the early stage of chemother-apy were independent predictors of cardiac adverse events in chemotherapy patients.The area under the ROC curve of the nomogram was 0.768(95%CI:0.693-0.843,P<0.001).Conclusion A nomogram based on age,pre-chemotherapy RDW,APTT,and EMAT at the early stage of chemotherapy is useful for early assessment of the risk of cardiac adverse events in chemotherapy patients.
